imatinib
Pronunciation: eye-MAT-ih-nib
A tyrosine kinase inhibitor drug used to treat Philadelphia chromosome-positive leukemias by blocking BCR-ABL protein activity.
Full Definition
Imatinib is a targeted therapy drug that specifically inhibits the BCR-ABL tyrosine kinase produced by the Philadelphia chromosome translocation. Originally developed for chronic myeloid leukemia, it has revolutionized treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in children when combined with chemotherapy. The drug works by binding to the ATP-binding site of the BCR-ABL protein, preventing its oncogenic activity. Common side effects include fluid retention, muscle cramps, and growth retardation in children.
Usage
Usage note: Generic name should be lowercase. Brand name Gleevec should be capitalized.
In Context
- "Imatinib was added to the chemotherapy protocol for this Philadelphia chromosome-positive case." — Treatment plan
- "Growth velocity monitoring is required for children receiving chronic imatinib therapy." — Follow-up guidelines